MRE11 and colorectal carcinoma: In particular, low MRE11 expression has been associated with improved oxaliplatin sensitivity and better progression-free survival in CRC patients [40,41], which might be translated to the treatment and clinical impact of the tumors developed in the context of a germline MRE11 pathogenic variant.